A recent ruling by a federal judge has halted Colorado's efforts to cap the price of Enbrel, a widely used medication manufactured by Amgen.
This decision directly affects a pricing strategy proposed by a state panel aimed at regulating the costs of pharmaceuticals.
The implications of this ruling may extend beyond Colorado, potentially influencing drug pricing regulations in other states.
Updates
Update at 12:54 UTC on 2026-07-02
STAT reported A federal judge blocked a Colorado state panel from placing a cap on the price of Enbrel, a blockbuster drug sold by Amgen.
Sources: STAT